MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network
Neuro-Oncology Advances · 01.01.2023 · 5 (1)
DOI: 10.1093/noajnl/vdad023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 05.03.2023. Verfasst von Satrajit Chakrabarty und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electrical and Systems Engineering, Washington University in St. Louis, St. Louis, MO, USA. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCRR NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Background
IDH mutation and 1p/19q codeletion status are important prognostic markers for glioma that are currently determined using invasive procedures. Our goal was to develop artificial intelligence-based methods to noninvasively determine molecular alterations from MRI.
Methods
Pre-operative MRI scans of 2648 glioma patients were collected from Washington University School of Medicine (WUSM; n = 835) and publicly available Brain Tumor Segmentation (BraTS; n = 378), LGG 1p/19q (n = 159), Ivy Glioblastoma Atlas Project (Ivy GAP; n = 41), The Cancer Genome Atlas (TCGA; n = 461), and the Erasmus Glioma Database (EGD; n = 774) datasets. A 2.5D hybrid convolutional neural network was proposed to simultaneously localize glioma and classify its molecular status by leveraging MRI imaging features and prior knowledge features from clinical records and tumor location. The models were trained on 223 and 348 cases for IDH and 1p/19q tasks, respectively, and tested on one internal (TCGA) and two external (WUSM and EGD) test sets.
Results
For IDH, the best-performing model achieved areas under the receiver operating characteristic (AUROC) of 0.925, 0.874, 0.933 and areas under the precision-recall curves (AUPRC) of 0.899, 0.702, 0.853 on the internal, WUSM, and EGD test sets, respectively. For 1p/19q, the best model achieved AUROCs of 0.782, 0.754, 0.842, and AUPRCs of 0.588, 0.713, 0.782, on those three data-splits, respectively.
Conclusions
The high accuracy of the model on unseen data showcases its generalization capabilities and suggests its potential to perform “virtual biopsy” for tailoring treatment planning and overall clinical management of gliomas.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Electrical and Systems Engineering, Washington University in St. Louis, St. Louis, MO, USA.
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
- Mallinckrodt Institute of Radiology and Institute for Informatics, Washington University School of Medicine, St. Louis, USA.
ORCID-Profile: Satrajit Chakrabarty, Aristeidis Sotiras
Förderung
- NIH HHS
- NCRR NIH HHS
- NINDS NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Chakrabarty, S., LaMontagne, P., Shimony, J., Marcus, D. S., & Sotiras, A. (2023). MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad023
Vancouver
Chakrabarty S, LaMontagne P, Shimony J, Marcus DS, Sotiras A. MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network. Neuro-Oncology Advances. 2023;5(1). doi:10.1093/noajnl/vdad023
BibTeX
@article{Chakrabarty2023,
author = {Chakrabarty, Satrajit and LaMontagne, Pamela and Shimony, Joshua and Marcus, Daniel S and Sotiras, Aristeidis},
title = {MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network},
journal = {Neuro-Oncology Advances},
year = {2023},
volume = {5},
number = {1},
doi = {10.1093/noajnl/vdad023}
}
EUVIMED